Document Detail


Intravitreous bevacizumab treatment for macular edema due to central retinal vein occlusion.
MedLine Citation:
PMID:  22668313     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To investigate the visual and anatomical effects of intravitreal bevacizumab treatment of macular edema due to central retinal vein occlusion (CRVO).
METHODS: Data were collected by medical chart review for 35 consecutive patients (35 eyes) with CRVO-induced macular edema treated with intravitreal bevacizumab in 2007-2010 and followed for at least 6 months. All patients received 3-4 loading doses (1.25 mg) with follow-up every 6-8 weeks and repeated injections as necessary.
RESULTS: Mean patient age was 65.5 years (SD 13.5); mean follow-up time, 17.7 months (SD 10.8); mean number of injections, 9.3 (SD 5). Mean logMAR visual acuity (VA) improved from 0.9 (SD 0.49) at baseline to 0.7 (SD 0.5) at the last visit; corresponding Snellen values were 6/98 and 6/15 (p = 0.009). Four patients (11%) lost ≥3 lines, and 13 patients (37%) gained ≥3 lines. There was a positive correlation between initial and final VA (p < 0.0005). Central macular thickness (CMT) measured 489.5 microns (SD 175) at baseline and 395 microns (SD 223) at the last visit (p = 0.24). VA gain was positively correlated with CMT reduction (p < 0.0001).
CONCLUSIONS: Intravitreal bevacizumab treatment of CRVO-induced macular edema improves vision, especially in patients with good initial VA.
Authors:
Ruth Axer-Siegel; Assaf Dotan; Karin Mimouni; Elite Bor; Dov Weinberger; Dan Haim Bourla
Related Documents :
17848233 - Esophageal replacement in the neonatal period in infants with esophageal atresia and tr...
17063303 - Laparoscopic gastric bypass performed with the da vinci intuitive robotic system: preli...
2775633 - In situ bypass to the dorsalis pedis and tibial arteries at the ankle.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2012-06-05
Journal Detail:
Title:  Current eye research     Volume:  37     ISSN:  1460-2202     ISO Abbreviation:  Curr. Eye Res.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-06     Completed Date:  2013-01-15     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8104312     Medline TA:  Curr Eye Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  818-22     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel. seegs@netvision.net.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage*
Female
Fluorescein Angiography
Fundus Oculi
Humans
Intravitreal Injections
Macular Edema / diagnosis,  drug therapy*,  etiology
Male
Retinal Vein Occlusion / complications*,  diagnosis
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A new audio processor for combined electric and acoustic stimulation for the treatment of partial de...
Next Document:  Effect of ovarian activity on orthodontic tooth movement and gingival crevicular fluid levels of int...